Ahmer Asif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmer Asif has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Adnan I. Qureshi
Department of Neurology, University of Missouri, Columbia, Missouri; Zeenat Qureshi Stroke Institute, St. Cloud, Minnesota
2 shared publicationsEmrah Aytac
Department of Neurology, Firat University, Elazig, Turkey; Zeenat Qureshi Stroke Institute, St. Cloud, Minnesota
2 shared publicationsErdem Gurkas
Department of Neurology, Gulhane Training and Research Hospital, Ankara, Turkey; Zeenat Qureshi Stroke Institute, St. Cloud, Minnesota
2 shared publications- Asad Ali
Internal Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, PAK
1 shared publication Brandi R. French
Department of Neurology, University of Missouri, Columbia, Missouri
1 shared publicationCamilo R. Gomez
Department of Neurology, University of Missouri, Columbia, Missouri
1 shared publication
Latest Publications
- 1 December 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (12) , 104362
Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke
- 1 December 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (12) , 104362
Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke
- 29 September 2019
- Published by Wiley in Journal of Neuroimaging
- Vol. 30 (1) , 90-96
Assessment of Cerebral Vasodilatory Capacity as Part of Catheter‐Based Cerebral Angiography
BACKGROUND AND PURPOSE: Cerebral vasodilatory capacity assessment for risk stratification in patients with extracranial arterial stenosis or occlusion may be useful. We describe a new method that assesses cerebral vasodilatory capacity as part of catheter‐based cerebral angiography.METHODS: We prospectively assessed regional cerebral blood volume (rCBV) in the arterial distribution of interest using a controlled contrast injection in the common carotid or the subclavian arteries. rCBV maps were created using a predefined algorithm based on contrast distribution in the venous phase (voxel size: .466 mm3). rCBV maps were acquired again after selective administration of intra‐arterial nicardipine (2.0 mg) distal to the stenosis. Two independent observers graded the change in rCBV in 10 predefined anatomical regions within the tributaries of the artery of interest (0 = reduction, 1 = no change, 2 = increase) and total rCBV change scores were summated.RESULTS: Twenty‐five patients with internal carotid artery stenosis (n = 18; 0‐90% in severity) or extracranial vertebral artery stenosis (n = 7; 0‐100% in severity) were assessed. There was an increase in rCBV in a tributary of the artery of interest in 18 of 25 after intra‐arterial nicardipine (mean score: 11.98; range 0‐19.5). There was no change or decrease in rCBV in 7 of 25 patients. The mean rCBV change score was similar in patients with an assessment of internal carotid artery or vertebral artery distributions (12.2 ± 5.3; 11.4 ± 2.5; P = .68).CONCLUSION: Selective vasodilatory response to intra‐arterial nicardipine in the affected arterial distribution during catheter‐based cerebral angiography may provide new data for risk stratification.
- 29 September 2019
- Published by Wiley in Journal of Neuroimaging
- Vol. 30 (1) , 90-96
Assessment of Cerebral Vasodilatory Capacity as Part of Catheter‐Based Cerebral Angiography
BACKGROUND AND PURPOSE: Cerebral vasodilatory capacity assessment for risk stratification in patients with extracranial arterial stenosis or occlusion may be useful. We describe a new method that assesses cerebral vasodilatory capacity as part of catheter‐based cerebral angiography.METHODS: We prospectively assessed regional cerebral blood volume (rCBV) in the arterial distribution of interest using a controlled contrast injection in the common carotid or the subclavian arteries. rCBV maps were created using a predefined algorithm based on contrast distribution in the venous phase (voxel size: .466 mm3). rCBV maps were acquired again after selective administration of intra‐arterial nicardipine (2.0 mg) distal to the stenosis. Two independent observers graded the change in rCBV in 10 predefined anatomical regions within the tributaries of the artery of interest (0 = reduction, 1 = no change, 2 = increase) and total rCBV change scores were summated.RESULTS: Twenty‐five patients with internal carotid artery stenosis (n = 18; 0‐90% in severity) or extracranial vertebral artery stenosis (n = 7; 0‐100% in severity) were assessed. There was an increase in rCBV in a tributary of the artery of interest in 18 of 25 after intra‐arterial nicardipine (mean score: 11.98; range 0‐19.5). There was no change or decrease in rCBV in 7 of 25 patients. The mean rCBV change score was similar in patients with an assessment of internal carotid artery or vertebral artery distributions (12.2 ± 5.3; 11.4 ± 2.5; P = .68).CONCLUSION: Selective vasodilatory response to intra‐arterial nicardipine in the affected arterial distribution during catheter‐based cerebral angiography may provide new data for risk stratification.
- Open Access
- 16 July 2018
- Published by Springer Nature in Cureus
- Vol. 10 (7) , e2986
Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease
The prolonged use of levodopa for treating Parkinson’s disease is associated with motor and nonmotor complications. These include wearing-off, delayed-on, partial-on, no-on, and on-off phenomena. In the wearing-off effect, symptoms return before a patient's next scheduled dose of levodopa. Patients may present with motor, sensory, or autonomic fluctuations. In this report, we present a female patient experiencing numbness of lips and slurred speech as a symptom of wearing-off effect. The major differential for sudden numbness of lips and slurred speech includes transient ischemic attacks. Therefore, it is imperative to identify the cause of these episodes so that appropriate treatment can be initiated. Our patient underwent extensive cardiac and neurological investigations, the findings of which were unremarkable. Her symptoms were likely due to levodopa wearing-off. Her condition improved on changing her levodopa to a sustained release form with more frequent dosing along with the addition of ropinirole to her treatment regimen.
- 16 July 2018
- Published by Springer Nature in Cureus
- Vol. 10 (7) , e2986
Open AccessSlurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease
The prolonged use of levodopa for treating Parkinson’s disease is associated with motor and nonmotor complications. These include wearing-off, delayed-on, partial-on, no-on, and on-off phenomena. In the wearing-off effect, symptoms return before a patient's next scheduled dose of levodopa. Patients may present with motor, sensory, or autonomic fluctuations. In this report, we present a female patient experiencing numbness of lips and slurred speech as a symptom of wearing-off effect. The major differential for sudden numbness of lips and slurred speech includes transient ischemic attacks. Therefore, it is imperative to identify the cause of these episodes so that appropriate treatment can be initiated. Our patient underwent extensive cardiac and neurological investigations, the findings of which were unremarkable. Her symptoms were likely due to levodopa wearing-off. Her condition improved on changing her levodopa to a sustained release form with more frequent dosing along with the addition of ropinirole to her treatment regimen.